The overall objective of this study is to use patient-centered in vitro and in vivo models to answer the fundamental question of whether or not pathogenic mutations in BRCA1/2 result in an increased risk of CV disease

Inclusion Criteria

• ≥18 years of age

• Initial diagnosis of Breast Cancer in 2005 or later

• Documented BRCA testing (results from a local laboratory are acceptable) showing

  • confirmation of a germline mutation in BRCA1 or BRCA2 that is predicted or suspected to be deleterious OR
  • confirmation that no mutation was detected in BRCA1 or BRCA2

• Non-carriers will have been treated with an anthracycline-based chemotherapy regimen; carriers may or may not have been treated with an anthracycline-based chemotherapy regimen.

• Approximately at least 12 months from initiation of adjuvant treatment or neo-adjuvant chemotherapy

• Able to provide informed consent

Exclusion Criteria

• Stage IV Breast Cancer

• Genetic testing confirming a variant of unknown significance (VUS) or benign polymorphism in BRCA1 or BRCA2

• V02 Testing contraindicated for any reason, including:

  • Myocardial infarction (within past 3 months)
  • High-risk unstable angina;
  • High-risk or uncontrolled cardiac arrhythmias;
  • Symptomatic severe aortic stenosis;
  • Uncontrolled symptomatic heart failure;
  • Acute pulmonary embolus or pulmonary infarction;
  • Acute myocarditis or pericarditis;
  • Acute aortic dissection;
  • Coronary revascularization procedure within the past three months;
  • Uncontrolled hypertension, defined as systolic blood pressure ≥ 180mmHg or diastolic blood pressure ≥ 100mmHg;
  • Clinically significant valvular heart disease (severe stenosis or regurgitation);
  • Known aortic aneurysm; or
  • Any other condition which, in the opinion of the investigator, may impede testing of the study hypothesis or make it unsafe to engage in the V02 test

• Women who are pregnant

• Any other clinically significant medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent

Initial diagnosis of Breast Cancer in 2005 or later BRCA testing documenting either germline mutation in BRCA1/BRCA2 or no mutation in BRCA1/2.